Results 141 to 150 of about 8,876 (157)

Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms

Biochemical and Biophysical Research Communications, 2002
Cytochrome P450 (CYP) 2C8 and 2C9 are polymorphic enzymes. The CYP2C8*3 and CYP2C9*2 are the major variant alleles in Caucasian populations. The enzymes encoded by these variant alleles have impaired function for the metabolism of several drug substrates.
Umit, Yasar, Stefan, Lundgren, Erik, Eliasson, Anna, Bennet, Björn, Wiman, Ulf, de Faire, Anders, Rane   +6 more
openaire   +2 more sources

CYP2C8 polymorphism frequencies among malaria patients in Zanzibar

European Journal of Clinical Pharmacology, 2005
The determination of the prevalence of the CYP2C8 main alleles in a typical set of malaria patients in Zanzibar, as these patients represent a typical population exposed to amodiaquine, an antimalarial mainly metabolized by CYP2C8. Also, to determine for the first time the frequencies of CYP2C8 alleles in native African populations.Polymerase chain ...
I, Cavaco, J, Strömberg-Nörklit, A, Kaneko, M I, Msellem, M, Dahoma, V L, Ribeiro, A, Bjorkman, J P, Gil   +7 more
openaire   +2 more sources

Response and neurologic toxicity to taxano regarding to CYP2C8*3 and CYP2C8*2 polymorphisms in Peruvian breast cancer cases.

Journal of Clinical Oncology, 2015
e12520 Background: An option in the BC neoadyuvant treatment is paclitaxel, being the goal achieving pathological complete response (pRC).
Cindy Alcarraz, Carlos Castaneda Altamirano, Henry Gomez, Amparo Zavaleta, Carol Flores, Miluska Castillo Garcia, Ketty Dolores Cerna, Julio E. Abugattas Saba, Tatiana Vidaurre   +8 more
openaire   +1 more source

Abstract 3016: Tucatinib inhibits CYP3A, CYP2C8 and P-gp-mediated elimination and is impacted by CYP2C8 inhibition in healthy volunteers

Cancer Research, 2020
Abstract Background: Tucatinib is a potent, highly selective HER2 tyrosine kinase inhibitor in development for the treatment of patients with HER2+ metastatic breast cancer. In vitro metabolism studies suggest that drug metabolizing enzymes CYP2C8 and CYP3A play a role in tucatinib metabolism. Tucatinib exhibits competitive inhibition of
Ariel R. Topletz-Erickson, Anthony Lee, Hao Sun, JoAl Mayor, Luke Walker, Christopher J. Endres   +5 more
openaire   +1 more source

CYP2C8 Activity Recovers within 96 Hours after Gemfibrozil Dosing: Estimation of CYP2C8 Half-Life Using Repaglinide as an in Vivo Probe

Drug Metabolism and Disposition, 2009
Gemfibrozil 1-O-beta-glucuronide is a mechanism-based inhibitor of cytochrome P450 2C8. We studied the recovery of CYP2C8 activity after discontinuation of gemfibrozil treatment using repaglinide as a probe drug, to estimate the in vivo turnover half-life of CYP2C8. In a randomized five-phase crossover study, nine healthy volunteers ingested 0.25 mg of
Janne T, Backman, Johanna, Honkalammi, Mikko, Neuvonen, Kaisa J, Kurkinen, Aleksi, Tornio, Mikko, Niemi, Pertti J, Neuvonen   +6 more
openaire   +2 more sources

Inhibitory Effects of Danshen components on CYP2C8 and CYP2J2

Chemico-Biological Interactions, 2018
The use of Chinese herbal medicines and natural products has become increasingly popular in both China and Western societies as an alternative medicine for the treatment of diseases or as a health supplement. Danshen, the dried root of Salvia miltiorrhiza (Fam.Labiatae), which is rich in phenolic acids and tanshinones, is a widely used herbal medicine ...
Mei-Juan, Xu, Li-Feng, Jiang, Ting, Wu, Ji-Hong, Chu, Yi-Dan, Wei, Ji-Ye, Aa, Guang-Ji, Wang, Hai-Ping, Hao, Wen-Zheng, Ju, Ping, Li   +9 more
openaire   +2 more sources

Polymorphisms in CYP2C8 and CYP3A5 genes in the Nigerian population

Drug Metabolism and Pharmacokinetics, 2017
Polymorphisms in CYP2C8 and CYP3A5 genes have implications for responses elicited by the ingestion of some xenobiotics, the metabolism of which are mediated by these enzymes. CYP2C8*2, CYP2C8*3, CYP3A5*3, CYP3A5*6 and CYP3A5*7 are a few functionally-relevant variants of these genes which this study provides data for, in the Nigerian population.
Ayorinde Adehin, Oluseye Oladotun Bolaji, Martin A. Kennedy   +2 more
openaire   +2 more sources

Stereoselective interaction between the CYP2C8 inhibitor gemfibrozil and racemic ibuprofen

European Journal of Clinical Pharmacology, 2007
Ibuprofen, a nonsteroidal anti-inflammatory agent, is metabolised in vitro by cytochrome P450 (CYP) 2C8 and 2C9. We studied the possible effect of gemfibrozil, an in vivo inhibitor of CYP2C8, on the pharmacokinetics of ibuprofen in healthy volunteers.In a randomised two-phase crossover study, 10 healthy volunteers took 600 mg gemfibrozil or placebo ...
Aleksi, Tornio, Mikko, Niemi, Pertti J, Neuvonen, Janne T, Backman   +3 more
openaire   +2 more sources

Gemfibrozil Inhibits CYP2C8-Mediated Cerivastatin Metabolism in Human Liver Microsomes

Drug Metabolism and Disposition, 2002
To explore the mechanism of the interaction between gemfibrozil and cerivastatin, the enzyme mapping of the oxidative metabolism of cerivastatin and the effect of gemfibrozil on cerivastatin metabolism were studied using human liver microsomes and expressed cytochrome p450 (p450) CYP2C8 and 3A4 isoforms. Based on studies with isoform-selective chemical
Jun-Sheng, Wang, Mikko, Neuvonen, Xia, Wen, Janne T, Backman, Pertti J, Neuvonen   +4 more
openaire   +2 more sources

Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide

European Journal of Clinical Pharmacology, 2006
Pioglitazone, a thiazolidinedione antidiabetic, inhibits cytochrome P450 (CYP) 2C8 and CYP3A4 enzymes in vitro. Repaglinide, a meglitinide analogue antidiabetic, is metabolised by CYP2C8 and CYP3A4. In patients with type 2 diabetes, the pioglitazone-repaglinide combination has acted synergistically on glycaemic parameters.
Lauri I, Kajosaari, Tiina, Jaakkola, Pertti J, Neuvonen, Janne T, Backman   +3 more
openaire   +2 more sources